Three Cases of Hemodialysis Patients Receiving High-Dose Ceftriaxone: Serum Concentrations and Its Neurotoxicity

Inoue, Yui; Doi, Yasufumi; Arisato, Tetsuya; Sugioka, Sayaka; Koga, Kenichi; Nishioka, Keisuke; Sugawara, Akira

doi:10.1016/j.ekir.2017.03.009

Cited by 22 publications

(23 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are also scattered reports of AAE caused by CTRX, and according to an adverse drug reaction database study in France, the serious CNS adverse effects caused by CTRX and CFPM were reported to be similar [ 12 ]. AAE with CTRX has been reported more frequently in the elderly and patients with chronic kidney disease and is more likely to occur when high doses are given and blood and cerebrospinal fluid (CSF) concentrations are high [ 13 , 14 , 15 ].…”

Section: Tdm Of Ceftriaxonementioning

confidence: 99%

Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan

Ebihara

Hamada

Kato

et al. 2022

IJERPH

View full text Add to dashboard Cite

Under the Japanese health insurance system, medicines undergoing therapeutic drug monitoring (TDM) can be billed for medical fees if they meet the specified requirements. In Japan, TDM of vancomycin, teicoplanin, aminoglycosides, and voriconazole, which are used for the treatment of infectious diseases, is common practice. This means the levels of antibiotics are measured in-house using chromatography or other methods. In some facilities, the blood and/or tissue concentrations of other non-TDM drugs are measured by HPLC and are applied to treatment, which is necessary for personalized medicine. This review describes personalized medicine based on the use of chromatography as a result of the current situation in Japan.

show abstract

Section: Tdm Of Ceftriaxonementioning

confidence: 99%

Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan

Ebihara

Hamada

Kato

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…There are also scattered reports of AAE caused by CTRX, and according to an adverse drug reaction database study in France, serious CNS adverse effects caused by CTRX and CFPM were reported to be similar [11]. AAE with CTRX has been reported more frequently in the elderly and patients with chronic kidney disease and is more likely to occur when high doses are given and blood and cerebrospinal fluid (CSF) concentrations are high [12][13][14].…”

Section: Characteristics Of Ceftriaxone and Significance Of Tdmmentioning

confidence: 99%

Potential Clinical Benefits of TDM of Antimicrobials in Japan

Ebihara¹,

Hamada²,

Maruyama³

et al. 2022

Preprint

View full text Add to dashboard Cite

Under the Japanese health insurance system, medicines undergoing therapeutic drug monitoring (TDM) can be billed for medical fees if they meet the specified requirements. In Japan, TDM of vancomycin, teicoplanin, aminoglycosides, and voriconazole, which are used for the treatment of infectious diseases, is common practice. This means the levels of antimicrobial agents are measured in-house using chromatography. This review describes personalized medicine based on the use of chromatography as a result of the current situation in Japan.

show abstract

“…Nevertheless, ceftriaxone is not recommended to be administered for neonates <28 days due to the risk of developing biliary and cardiopulmonary adverse events (Donnelly and others 2017). Besides, recent study reported ceftriaxone-induced neurotoxicity in patients with end-stage renal disease resulting from the delayed clearance of the drug (Inoue and others 2017). In rare cases, ceftriaxone can cause drug-induced hemolytic anemia (Tasch & Gonzalez-Zayaz 2017).…”

Section: Ceftriaxone: β-Lactam Antibioticmentioning

confidence: 99%

Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury

et al. 2020

View full text Add to dashboard Cite

Traumatic brain injury (TBI) remains a significant leading cause of death and disability among adults and children globally. To date, there are no Food and Drug Administration–approved drugs that can substantially attenuate the sequelae of TBI. The innumerable challenges faced by the conventional de novo discovery of new pharmacological agents led to the emergence of alternative paradigm, which is drug repurposing. Repurposing of existing drugs with well-characterized mechanisms of action and human safety profiles is believed to be a promising strategy for novel drug use. Compared to the conventional discovery pathways, drug repurposing is less costly, relatively rapid, and poses minimal risk of the adverse outcomes to study on participants. In recent years, drug repurposing has covered a wide range of neurodegenerative diseases and neurological disorders including brain injury. This review highlights the advances in drug repurposing and presents some of the promising candidate drugs for potential TBI treatment along with their possible mechanisms of neuroprotection. Edaravone, glyburide, ceftriaxone, levetiracetam, and progesterone have been selected due to their potential role as putative TBI neurotherapeutic agents. These drugs are Food and Drug Administration–approved for purposes other than brain injuries; however, preclinical and clinical studies have shown their efficacy in ameliorating the various detrimental outcomes of TBI.

show abstract

Three Cases of Hemodialysis Patients Receiving High-Dose Ceftriaxone: Serum Concentrations and Its Neurotoxicity

Cited by 22 publications

References 14 publications

Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan

Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan

Potential Clinical Benefits of TDM of Antimicrobials in Japan

Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury

Contact Info

Product

Resources

About